顶级内分泌学期刊对报告指南的背书与临床试验注册仍不一致
研究评估2021年Scopus CiteScore「内分泌、肥胖与代谢」子分类前100种期刊对报告指南(RGs)的推荐/要求及临床试验注册情况,通过分析「作者须知」并联系期刊确认接受文章类型。结果显示CONSORT最常被提及(46种推荐、36种要求),PRISMA被61种推荐、19种要求,77种要求临床试验注册。结论认为顶级内分泌学期刊对RGs的背书缺乏一致性,可能损害透明度并引入偏倚。
要点
- CONSORT被46种期刊推荐、36种期刊要求 adherence。
- PRISMA被61种期刊推荐、19种期刊要求 adherence。
- 77种期刊要求临床试验注册。
核心结论
- 顶级内分泌学期刊对报告指南的背书缺乏一致性,可能损害透明度并引入偏倚。
- 作者建议该领域期刊编辑更严格地执行经过验证的报告指南,以提高已发表研究的质量。
研究设计与样本
- 利用2021年Scopus CiteScore工具识别「内分泌、肥胖与代谢」子分类前100种期刊。
- 分析每种期刊「作者须知」中关于EQUATOR Network所列部分报告指南及临床试验注册的声明。
- 声明记录为「未提及」「推荐」「不要求」或「要求」四类。
- 联系每种期刊确认其接受的文章类型,以避免不公平评估。
主要发现
- 100种期刊中,CONSORT是最常被提及的指南,46种期刊推荐 adherence,36种期刊要求 adherence。
- PRISMA被61种期刊推荐,被19种期刊要求。
- 77种期刊要求临床试验注册。
关键数值与推荐
- CONSORT:46种期刊推荐 adherence,36种期刊要求 adherence。
- PRISMA:61种期刊推荐,19种期刊要求。
- 临床试验注册:77种期刊要求。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究的主要局限性是研究范围狭窄,导致普适性低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Clinicians rely on evidence-based research for clinical practice to ensure safe, efficacious patient care. Reporting guidelines (RGs) and clinical trial registration improve the quality of this research by increasing transparency and reducing the risk of biases. The extent to which endocrinology journals adopt the use of these tools is unclear. Therefore, the primary outcome of this study is to assess the recommendation and requirement of RGs, and the secondary outcome is to assess clinical trial registration in the top endocrinology journals. METHODS: The top 100 journals in the "Endocrinology, Obesity, and Metabolism" subcategory were identified using the 2021 Scopus CiteScore tool. The "instructions to authors" of each journal were analyzed for statements regarding select RGs outlined by the Enhancing the Quality and Transparency of Health Research Network, as well as clinical trial registration. Statements were recorded as "Not Mentioned," "Recommended," "Does Not Require," or "Required." To prevent unfair assessment, each journal was contacted to confirm the article types that are accepted. RESULTS: Of 100 journals examined, Consolidated Standards of Reporting Trials was the most commonly mentioned guideline, with 46 journals recommending adherence and 36 journals requiring adherence. Preferred Reporting Items for Systematic Reviews and Meta-Analyses was recommended by 61 journals and required by 19 journals. Finally, 77 journals required clinical trial registration. CONCLUSION: Our study reveals a lack of consistent endorsement of RGs in top endocrinology journals. This may undermine transparency and introduce bias. The main limitation of this study is the narrow scope of the study leading to a low generalizability. We suggest that journal editors in this field enforce validated RGs more strictly to improve the quality of published research.
引用
- Bratten C, Khan H, King D, et al. Endorsement of reporting guidelines and trial registration remains inconsistent across top endocrinology journals. J Clin Epidemiol. 2025. PMID: 40398689. doi:10.1016/j.jclinepi.2025.111835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。